Official ESCRS | European Society of Cataract & Refractive Surgeons
Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance
ISTANBUL escrs









Take a look inside the London 2014 Congress

video-icon

Then register to join us
in Barcelona!





Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

The effects of fluoxetine on the treatment of amblyopia

Poster Details

First Author: M.Talebnejad IRAN

Co Author(s):    M. Sharif   K. Rastegar                 

Abstract Details

Purpose:

Since it has been found that fluoxetine may increase neuronal plasticity. This research considered its effect on treatment of amblyopia. We assessed the effect of this medication on various aspects of visual functions including contrast sensitivity, streropsis as well as its impact on VEP latency 15 and 60 minutes.

Setting:

Poostchi Eye Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Methods:

Following ethical approval, thirty –five amblyopic cases were recruited. They were divided into two groups of medication and placebo that were under treatment for 90 days. In both groups occlusion of healthy eye was done for 4-6 hours a day together with visual activities such as reading, watching TV and playing video games. Visual acuity (VA), contrast sensitivity, stereopsis and WEP were assessed before and after treatment.

Results:

Following ethical approval, thirty –five amblyopic cases were recruited. They were divided into two groups of medication and placebo that were under treatment for 90 days. In both groups occlusion of healthy eye was done for 4-6 hours a day together with visual activities such as reading, watching TV and playing video games. Visual acuity (VA), contrast sensitivity, stereopsis and WEP were assessed before and after treatment.

Conclusions:

Fluoxetine is and effective treatment of amblyopia following the critical period significantly however further studies are required.

Financial Disclosure:

NONE

Back to Poster listing